Nepenthe Bioscience

Nepenthe Bioscience is a pre-clinical stage biotechnology company dedicated to developing transformative therapies for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS). The company's research centers on the TDP-43/Stathmin-2 axis, addressing the loss of Stathmin-2 protein that occurs when TDP-43 mislocalizes in diseased neurons. By utilizing gene therapy and RNA-based approaches, Nepenthe aims to restore axonal health and prevent motor neuron degeneration. Founded by leading neuroscientists from Harvard Medical School and Boston Children's Hospital, the company is positioning itself at the forefront of precision medicine for proteinopathies.